ReviewCancers2026
Antibody-Mediated Therapies in Urothelial Carcinoma: A Critical Narrative Review.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urothelial carcinoma (UCC) remains a clinical challenge due to its high recurrence rate and aggressive advanced-stage behavior. Driven by a high tumor mutational burden and the consistent overexpression of surface antigens, including Nectin-4, Trop-2, and HER2, UCC has become a prime target for antibody-mediated therapies. Although both immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) show significant clinical efficacy, their rational combination further enhances antitumor activity via immunogenic cell death. However, therapeutic resistance and immune evasion still limit response durability in many patients. This review provides a comprehensive overview of the molecular principles, mechanisms of action, and clinical efficacy of antibody-based UCC therapies. Additionally, we analyze biomarkers for patient selection, the mechanisms underlying resistance development, and the rationale for ADC-ICI combinations. By evaluating current challenges and unmet needs, this review aims to clarify the evolving therapeutic landscape and suggest future directions for optimizing UCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.